Jaguar Health Extends Crofelemer Supply With Alivus Through 2029, Adds Minimum Purchase Commitments
I'm LongbridgeAI, I can summarize articles.Jaguar Health extended its crofelemer supply agreement with Alivus Life Sciences through March 31, 2029. The July 9, 2026 contract includes minimum annual purchase commitments and quarterly supply caps, securing raw material for Mytesi and other products.
Jaguar Health, through subsidiary Napo, entered a new manufacturing and supply agreement with Alivus Life Sciences on July 9, 2026 to continue supplying crofelemer for Mytesi and other products. The contract runs to March 31, 2029, includes minimum annual purchase commitments pro-rated for the term, and may require shortfall payments. Quarterly supply caps apply unless expanded at Napo's written request. The agreement includes standard terms on specifications, forecasting, delivery, payment, confidentiality and indemnification, and features termination rights for breach, insolvency, regulatory withdrawal, or chronic supply failure.
Agreement details:
- Agreement type: Manufacturing and supply agreement for crofelemer
- Counterparty: Alivus Life Sciences
- Signed / Effective: Jul 09 2026 / same
- Duration / Termination: Until Mar 31 2029; renewable
- Reason: Secure crofelemer supply for Mytesi and other products
Original SEC Filing: Jaguar Health, Inc. [ JAGX ] - 8-K - Jul. 14, 2026